Articles & Video
REPORT: Impacts of Decentralized Clinical Trials 2021
Explore the Clinical Trials Series global research study into adoption and impacts on patients, speed and cost of decentralized clinical trials.
Clinical Trials Content Library: Whitepapers and Reports Collection
Explore our collection of exclusive whitepapers and reports covering the hottest topics in clinical trials with one simple registration.
aThread buys inVibe to expand decentralized trials business
Trial tech firm Thread has acquired inVibe to add “voice research technology” to its decentralized offering to drug study sponsors and CROs.
Icon predicts 2022 revenue surge citing market and PRA acquisition
Icon says revenue and earnings will soar in 2022 thanks to growing demand for trial services and the contribution from recent acquisition PRA Health Sciences.
‘New’ CRO PoraGene to target drug and gene therapy sector
Newly rebranded CRO ProtaGene has set out to establish itself as a full-service partner for biopharmaceutical and gene therapy developers.
Cato and Pharm-Olam merge to target small and mid-sized pharma
Cato SMS and Pharm-Olam have merged in a bid to capture a bigger share of the small and mid-sized clinical services market.
Novalix to turn Sanofi Strasbourg site into HQ and R&D hub
CRO Novalix has acquired a Sanofi facility in Strasbourg, France it will turn into a headquarters and base of research services operations.
Intravacc to support development of nasal coronavirus vax set for clinical trials
Swedish biotech Intravacc will help the Dutch Leiden University Medical Center test a developmental coronavirus vaccine nasal spray.
COVID driving revs but patent loss and markets continue to shape pharma, IQVIA
COVID-19 will be a revenue driver and R&D focus for biopharma, but pre-pandemic factors like patent expiry and emerging markets continue to shape the sector says ICVIA.
Trials sector has more work to do to improve diversity in studies, Phesi
Efforts to make clinical trials more diverse have been more successful for some ethnic groups than for others according to AI-based analysis services provider, Phesi.
Deep Lens launches tech to help cancer drug developers focus on recruitment
Deep Lens has launched an AI-based platform designed to help sponsors identify the best study sites for cancer drug clinical trials.
Collaboration key to clinical trial sector growth post pandemic, ACRO
COVID-19 prompted a surge in public interest in taking part in studies and established decentralized trials as a viable model according to industry group ACRO.
US trials firm FHI Clinical plans to buy South Africa’s Triclinium
FHI Clinical plans to acquire Triclinium Clinical Development to increase its access to the South African trials market.
Labcorp forges latest AI deal, partnering with ConcertAI for cancer studies
Labcorp has teamed with ConcertAI to use the latter’s technology to optimize clinical trials of candidate cancer drug therapies.
IQVIA expands decentralized trials offering with dedicated nursing unit
IQVIA has expanded its decentralized trial offering with a dedicated mobile research nursing and blood sampling services unit.
Reify Health unveils tech to assess trial site enrolment diversity
Software firm Reify Health has launched a tool to help clinical trial sites determine how effectively they are engaging patients from underrepresented communities.
Global public network should replace for-profit CROs in antibiotic trials
A public clinical trial institutions would stimulate development of antibiotics more effectively than programs involving for profit CROs according to new research.
Cinven buys controlling share of BioAgilytix
Private equity investor Cinven has said it will buy a majority stake in US CRO BioAgilytix, citing growing demand for bioanalytical services as the motivation for the deal.
Decentralized trials firm says market is growing, citing executive survey
Research suggests drug companies and CROs will run more hybrid studies – those involving elements of remote participation – than traditional, site-based studies next year.
Generate Biomedicines raises $370m to advance AI drug discovery tech
Generate Biomedicines has raised $370 million to further develop its artificial intelligence (AI) drug discovery technology, expand its team and build labs.
COVID hit cell and gene therapy trials and suppliers but experts see signs of recovery
COVID-19 disrupted cell and gene therapy trials as well as the contractors and suppliers that support them, according to experts.